Cost-effectiveness of endovascular thrombectomy for acute ischemic stroke with established large infarct in Germany: a decision tree and Markov model
Language English Country Great Britain, England Media electronic
Document type Journal Article
PubMed
38906688
DOI
10.1136/jnis-2024-021837
PII: jnis-2024-021837
Knihovny.cz E-resources
- Keywords
- Economics, Stroke, Thrombectomy,
- MeSH
- Cost-Benefit Analysis * methods MeSH
- Endovascular Procedures * economics methods MeSH
- Ischemic Stroke * economics surgery epidemiology MeSH
- Quality-Adjusted Life Years MeSH
- Humans MeSH
- Markov Chains * MeSH
- Decision Trees * MeSH
- Aged MeSH
- Thrombectomy * economics methods MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Geographicals
- Germany epidemiology MeSH
BACKGROUND: Recent studies, including the TENSION trial, support the use of endovascular thrombectomy (EVT) in acute ischemic stroke with large infarct (Alberta Stroke Program Early Computed Tomography Score (ASPECTS) 3-5). OBJECTIVE: To evaluate the cost-effectiveness of EVT compared with best medical care (BMC) alone in this population from a German healthcare payer perspective. METHODS: A short-term decision tree and a long-term Markov model (lifetime horizon) were used to compare healthcare costs and quality-adjusted life years (QALYs) between EVT and BMC. The effectiveness of EVT was reflected by the 90-day modified Rankin Scale (mRS) outcome from the TENSION trial. QALYs were based on published mRS-specific health utilities (EQ-5D-3L indices). Long-term healthcare costs were calculated based on insurance data. Costs (reported in 2022 euros) and QALYs were discounted by 3% annually. Cost-effectiveness was assessed using incremental cost-effectiveness ratios (ICERs). Deterministic and probabilistic sensitivity analyses were performed to account for parameter uncertainties. RESULTS: Compared with BMC, EVT yielded higher lifetime incremental costs (€24 257) and effects (1.41 QALYs), resulting in an ICER of €17 158/QALY. The results were robust to parameter variation in sensitivity analyses (eg, 95% probability of cost-effectiveness was achieved at a willingness to pay of >€22 000/QALY). Subgroup analyses indicated that EVT was cost-effective for all ASPECTS subgroups. CONCLUSIONS: EVT for acute ischemic stroke with established large infarct is likely to be cost-effective compared with BMC, assuming that an additional investment of €17 158/QALY is deemed acceptable by the healthcare payer.
Clinic of Radiology Jessenius Faculty of Medicine Comenius University Martin Slovakia
Department of Neurology Aarhus University Hospital Aarhus Denmark
Department of Neurology and Stroke Unit La Paz University Hospital Madrid Spain
Department of Neurology Oslo University Hospital Oslo Norway
Department of Neurology University Medical Center Hamburg Eppendorf Hamburg Hamburg Germany
Department of Neuroradiology Heidelberg University Hospital Heidelberg Germany
Department of Neuroradiology Medical University of Innsbruck Innsbruck Tirol Austria
Hamburg Center for Health Economics Hamburg Germany
Laboratoire de Biométrie et Biologie Évolutive Université Lyon 1 Villeurbanne France
Service de Biostatistique Hospices Civils de Lyon Lyon France
The Norwegian University of Science and Technology Trondheim Norway
References provided by Crossref.org